GCCL (Global Clinical Central Laboratory), a South Korea-based prominent provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a USA based full-service contract research organization (CRO), announced that they had signed a strategic Memorandum of Understanding (MOU) pursuant to which aims to explore ways to strengthen their presence in the global clinical trial market.
In this agreement, GCCL and Frontage intend to consider opportunities to leverage the complementary services and networks of both companies to enhance competitiveness, particularly in the United States and Asia-Pacific (APAC) regions, while driving mutual growth.
To be specific, during the signing ceremony, the two companies reaffirmed their focus to collaboration as well as discussed opportunities for cooperation including joint clinical trial services in the U.S.A. and APAC regions, co-marketing and project support initiatives, development of new business opportunities, and additional initiatives.
Executive Statement
According to Dr. Nan Zhang, MD. PhD., Senior Vice President of Frontage, through this MOU, Frontage is hoping to develop a relationship with GCCL with the goal of reinforcing its presence in the APAC market and work closely with GCCL to providing faster and more efficient support for global clinical trials. By finding paths to collaborate and leverage the expertise and client networks of both companies, they would hope to further enhance the global clinical trial ecosystem and deliver high-quality, trusted services to our customers.
According to KwanGoo Cho, CEO of GCCL, they are hoping to develop a strategic relationship with Frontage focused on a spirit of collaboration. By working together, GCCL's bioanalytical and central lab expertise in APAC and Frontage's global capabilities may create new growth opportunities in the global clinical trial market for both companies. As always, they continue to aim to set a new standard in clinical trial execution and deliver meaningful analytical outcomes to their clients.